Navigation Links
TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
Date:9/16/2009

SAN DIEGO, Sept. 16 /PRNewswire/ -- TriLink BioTechnologies, Inc. (TriLink), announced that it is relaunching its oligonucleotide radiolabeling services. TriLink discontinued the service in May 2009 after ordering trends in 2008 suggested that the market may no longer require it. However, strong customer feedback led TriLink to bring back its radiolabeling services in September 2009.

"We've learned that no other suppliers have exactly our expertise in this area. We felt discontinuing this service left our customers with no viable option for highly modified radioactive oligonucleotides, and therefore we had to rescind our decision," said TriLink CEO, Dr. Richard Hogrefe.

TriLink leads the industry in unique modified nucleic acids and mid-scale oligonucleotide synthesis. High quality products and technical support are its key strengths. TriLink operates a fully GMP laboratory with a QSR environment. TriLink has over 13 years experience synthesizing radiolabeled DNA and RNA oligonucleotides. 35S and 3H labeling of both phosphodiester and phosphorothioate oligonucleotides are offered, as well as additional modifications.

About TriLink

TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 90 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email
'/>"/>

SOURCE TriLink BioTechnologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
2. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
3. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
4. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
5. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
6. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
7. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
8. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
9. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
10. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and SAN JOSE, California , January 15, ... developing antibody-drug conjugates for cancer, today announced the appointment of ... Dr Reynolds has over 20 years, development experience gained in ... Seattle Genetics. "I am delighted to welcome Tom ...
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... 2014 More than 5 million Americans ... in 3 seniors will die with Alzheimer’s or another ... figures have shocked many Americans into looking for ways ... these tragic age-related cognitive disorders. Jonathan Weisman, president of ...
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... April 12, 2011 Drs. Rodney Landreneau and ... non small cell lung cancer study at the 2011 Society ... Landreneau is Director of the Lung Center at UPMC Shady ... at UPMC Passavant Medical Center and Director of the Division ...
... 12, 2011 Biotech Medical, Inc. is set to ... SpectraSan™ "Hungry Enzymes". The products will be available for ... a Pet Stain & Odor Eraser, Spa & Whirlpool ... All-Purpose Cleaner & Degreaser, Glass & Stainless Steel Cleaner ...
... Dr. Fresh®, Inc., maker of the popular FireFly® children,s ... to raise awareness and funds for Smile Train, the ... company will donate $1 for every new "Like" on ... Smile Train.  The organization provides life-changing surgery for poor ...
Cached Biology Technology:Precision Therapeutics' ChemoFx® Demonstrates Significant Role in Selection of Chemotherapy Doublets in Non Small Cell Lung Cancer 2Biotech Medical, Inc. Introduces a Full Line of Enzyme Cleaners 2FireFly® Toothbrush Facebook Campaign Raises Funds for Smile Train 2
(Date:4/17/2014)... have hit on a novel method to help ... and most effective treatment possible., Kidney stones represent ... developing world. If left untreated, apart from being ... and other complications. In many patients treated successfully, ... more effective pathological approach to diagnosis and treatment ...
(Date:4/17/2014)... meeting painted a stark warning on the possible effects ... greenhouse effect 32 times that of carbon dioxide. Now ... substances act as fully regenerable electron acceptors which helps ... wetlands instead of being released to the atmosphere. However, ... it may enter into a vicious cycle to release ...
(Date:4/17/2014)... University researchers have detected new early-warning signs of the ... could have far-reaching implications for the diagnosis and treatment ... 25 million Americans. , "We had not expected to ... early stages," said Ann Elsner, professor and associate dean ... of the study. "We set out to study the ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2New technique detects microscopic diabetes-related eye damage 2New technique detects microscopic diabetes-related eye damage 3
... Gary Hoyle, PhD, professor, University of Louisville School of ... research to develop an effective medical treatment to counteract ... of terrorism. The National Institute of Environmental Health Sciences ... have awarded Hoyle $2.6 million over five-years to further ...
... in the southeastern United States, and for scientists trying to ... ) is not cooperating. So far botanists have ... plant to boiling water, dry heat up to 284 degrees ... coax them into germination. Nothing has worked. "Complete ...
... and conservation successes in the face of rapid environmental ... plants adapt to local climate. To improve scientists, ... 7, 2011 issue of Science helps define ... The National Science Foundation partly funded the study, ...
Cached Biology News:UofL researcher awarded $2.6 million NIH grant renewal 2Super-tough seed coat keeps Michaux's sumac on critically endangered list 2